Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Panadiplon (FG 10571) 是一种具有选择性的γ-氨基丁酸受体激动剂和5GABAA 的部分激动剂,是一种苯二氮卓类受体,可用于治疗焦虑症。Panadiplon 对 5GABAA 受体与 1GABAA 受体表现出选择性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 990 | 现货 | ||
5 mg | ¥ 2,500 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,890 | 现货 | ||
50 mg | ¥ 8,290 | 现货 | ||
100 mg | ¥ 11,200 | 现货 |
产品描述 | Panadiplon (FG 10571) is a selective gamma-aminobutyric acid receptor agonist and partial agonist of 5GABAA, a benzodiazepine receptor, used in the treatment of anxiety disorders.Panadiplon exhibits selectivity for 5GABAA receptors versus 1GABAA receptors. |
体外活性 | Panadiplon (10 μg/ml; 48 h; under normoxic conditions; hepatocytes) reduced ATP and glycogen levels by 40% but did not cause an increase in LDH leakage. Cells treated with panadiplon, then exposed to hypoxia conditions, showed a significant level of injury compared to normoxic control cultures, and a further reduction in ATP. No additional decrease in glycogen was observed. In an attempt to prevent panadiplon-mediated injury, glycolytic substrates (dihydroxyacetone or pyruvate) were included during normoxic and hypoxic incubations. Both treatments reduced the level of LDH leakage produced by panadiplon during hypoxia. Cotreatment did not generally increase ATP or glycogen levels (compared to panadiplon treatment groups) during hypoxia, though individual experiments showed a slight increase in ATP levels. During normoxia, both cotreatments with panadiplon resulted in significantly higher glycogen levels than in panadiplon cultures alone. These results suggest that cellular glycogen and subsequently ATP levels are reduced during panadiplon exposure, metabolically predisposing hepatocytes to hypoxic injury.[2] |
别名 | FG10571, FG-10571, FD-10571, PNU 78875, FG 10571, FD10571, FD 10571 |
分子量 | 335.36 |
分子式 | C18H17N5O2 |
CAS No. | 124423-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (149.09 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9819 mL | 14.9094 mL | 29.8187 mL | 74.5468 mL |
5 mM | 0.5964 mL | 2.9819 mL | 5.9637 mL | 14.9094 mL | |
10 mM | 0.2982 mL | 1.4909 mL | 2.9819 mL | 7.4547 mL | |
20 mM | 0.1491 mL | 0.7455 mL | 1.4909 mL | 3.7273 mL | |
50 mM | 0.0596 mL | 0.2982 mL | 0.5964 mL | 1.4909 mL | |
100 mM | 0.0298 mL | 0.1491 mL | 0.2982 mL | 0.7455 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Panadiplon 124423-84-3 Membrane transporter/Ion channel Neuroscience GABA Receptor FG10571 PNU78875 FG-10571 PNU-78875 FD-10571 PNU 78875 FG 10571 FD10571 FD 10571 Inhibitor inhibitor inhibit